N-苄基1-BOC-哌啶-4-甲酰胺 | 188527-08-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-苄基1-BOC-哌啶-4-甲酰胺
• 英文名称: tert-butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate
• 英文别名: N-Benzyl 1-boc-piperidine-4-carboxamide
• CAS: 188527-08-4
• 化学式: C₁₈H₂₆N₂O₃
• 分子量: 318.416
• InChiKey: AGQWIWVWFLIEKQ-UHFFFAOYSA-N

物化性质

• 熔点：
  84-86 °C
• 沸点：
  501.2±49.0 °C(Predicted)
• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Benzyl 1-BOC-piperidine-4-carboxamide
Synonyms: tert-Butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Benzyl 1-BOC-piperidine-4-carboxamide
CAS number: 188527-08-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C18H26N2O3
Molecular weight: 318.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-苄基1-BOC-哌啶-4-甲酰胺 在 盐酸 、 15-冠醚-5 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 4.5h， 生成 N-benzyl-N-ethylpiperidine-4-carboxamide hydrochloride
  参考文献：
  名称：

  Development of a Highly Potent, Novel M₅ Positive Allosteric Modulator (PAM) Demonstrating CNS Exposure: 1-((1H-Indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)

  摘要：

  A functional high throughput screen identified a novel chemotype for the positive allosteric modulation (PAM) of the muscarinic acetylcholine receptor (mAChR) subtype 5 (M-5). Application of rapid analog, iterative parallel synthesis efficiently optimized M-5 potency to arrive at the most potent M-5 PAMs prepared to date and provided tool compound 8n (ML380) demonstrating modest CNS penetration (human M-5 EC50 = 190 nM, rat M-5 EC50 = 610 nM, brain to plasma ratio (K-p) of 0.36).

  DOI：

  10.1021/jm500995y
• 作为产物：
  描述：

  4-哌啶甲酸 在 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 N-苄基1-BOC-哌啶-4-甲酰胺
  参考文献：
  名称：

  三取代的噻吩并[3,2 - b ]吡咯5-羧酰胺作为α病毒的强效抑制剂

  摘要：

  基孔肯雅病毒（CHIKV）是一种重新出现的载体传播的甲病毒，由伊蚊（Aedes mosquitoes ）传播给人类。尽管CHIKV再次成为流行病威胁，但目前尚无批准的CHIKV有效抗病毒治疗方法。在此，我们报告了一类噻吩并[3,2- b ]吡咯的合成与构效关系研究，以及发现了对噻吩[3,2 - b ]吡咯具有抑制活性的三取代噻吩[3,2 - b ]吡咯5-羧酰胺15c的发现。体外CHIKV感染。化合物15c显示出低微摩尔活性（EC 50的值 2μM）和有限的细胞毒性作用（CC50> 100μM），因此提供了大于32的选择性指数。值得注意的是，15c不仅控制了病毒RNA的产生，而且有效抑制了CHIKV nsP1，nsP3，衣壳和E2蛋白的表达。浓度低至2.5μM。更重要的是，15c还表现出了对其他临床上重要的alpha病毒（如O'nyong-nyong病毒和Sindbis病毒）的广谱抗病毒活性。

  DOI：

  10.1021/acs.jmedchem.5b01047

文献信息

• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。
• [EN] NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE MONOACYLGLYCÉROL LIPASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020035425A1

  公开（公告）日：2020-02-20

  The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using the compounds and methods of determining the monoacylglycerol lipase (MAGL) inhibitory activity of the compounds.

  这项发明提供了具有一般式(I)的新杂环化合物，其中A、L、X、m、n、R1和R2如本文所述，包括这些化合物的组合物，制造这些化合物的方法，使用这些化合物的方法以及确定这些化合物的单酰基甘油酶（MAGL）抑制活性的方法。
• [EN] NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE MONOACYLGLYCÉROL LIPASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020035424A1

  公开（公告）日：2020-02-20

  The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  这项发明提供了具有一般式(I)的新杂环化合物，其中A、L、X、m、n、R1和R2如本文所述，包括这些化合物的组合物，制造这些化合物的方法以及使用这些化合物的方法。
• ARBOVIRUS INHIBITORS AND USES THEREOF
  申请人：Larsen Scott

  公开号：US20120252807A1

  公开（公告）日：2012-10-04

  The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as inhibitors of arboviruses.

  本发明涉及化学化合物、其发现方法以及其治疗用途。具体而言，本发明提供了作为虫媒病毒抑制剂的化合物。
• Synthesis, Biological Evaluation, and Three-Dimensional in Silico Pharmacophore Model for σ₁ Receptor Ligands Based on a Series of Substituted Benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one Derivatives
  作者：Daniele Zampieri、Maria Grazia Mamolo、Erik Laurini、Chiara Florio、Caterina Zanette、Maurizio Fermeglia、Paola Posocco、Maria Silvia Paneni、Sabrina Pricl、Luciano Vio

  DOI：10.1021/jm900366z

  日期：2009.9.10

  Novel benzo[d]oxazol-2(3H)-one derivatives were designed and synthesized, and their affinities against σ receptors were evaluated. On the basis of 31 compounds, a three-dimensional pharmacophore model for the σ1 receptor binding site was developed using the Catalyst 4.9 software package. The best 3D pharmacophore hypothesis, consisting of one positive ionizable, one hydrogen bond acceptor, two hydrophobic

  设计并合成了新型的苯并[ d ]恶唑-2（3 H）-one衍生物，并评价了其对σ受体的亲和力。上的31种化合物，对于σ的三维药效团模型的基础1受体结合位点是使用Catalyst 4.9软件包开发的。最好的3D药效团假说由一个正离子化，一个氢键受体，两个疏水性芳香族和一个疏水性特征组成，提供了一个相关系数为0.89的3D-QSAR模型。最好的假设还通过三种独立的方法进行了验证，即Catacrst的CatScramble功能中包括的Fisher随机检验，留一法检验以及其他检验集的活性预测。所取得的结果将允许研究人员使用此3D药效团模型用于第二代高亲和力的σ的设计和合成1点的配体，以及发现其他铅化合物对此类受体的。